Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipients

Histopathology

Volumn 58, Issue 6, 2011, Pages 875-885

  Mackenzie, Katarzyna Anna ^a,b   Miller, Andrew Peter ^b   Hock, Barry David ^a   Gardner, Jacqui ^b   Simcock, Jeremy William ^b   Roake, Justin Allan ^b   Dachs, Gabi Ursula ^a   Robinson, Bridget Anne ^a,b   Currie, Margaret Jane ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Kidney transplantation; Skin neoplasms; Vascular endothelial growth factor A

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HYPOXIA INDUCIBLE FACTOR 1; MATRIX METALLOPROTEINASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; COHORT ANALYSIS; EXCISION; FEMALE; HOST RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; SKIN CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79956107288     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03845.x     Document Type: Article

References (42)

1. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N. Engl. J. Med. 2003; 348; 1681-1691.
2. Bouwes Bavinck JN, Hardie DR, Green A et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996; 61; 715-721.
3. Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol. 1999; 40(2 Pt 1); 177-186.
4. Bordea C, Wojnarowska F, Millard PR et al. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77; 574-579.
5. Carroll RP, Ramsay HM, Fryer AA et al. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am. J. Kidney Dis. 2003; 41; 676-683.
6. Giles GG, Marks R, Foley P. Incidence of non-melanocytic skin cancer treated in Australia. Br. Med. J. (Clin. Res. Ed.) 1988; 296; 13-17.
7. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J. Am. Acad. Dermatol. 2002; 47; 1-17; quiz 18-20
8. Lindelof B, Sigurgeirsson B, Gabel H et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br. J. Dermatol. 2000; 143; 513-519.
9. Moloney FJ, Comber H, O'Lorcain P et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br. J. Dermatol. 2006; 154; 498-504.
10. Ho WL, Murphy GM. Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients. Br. J. Dermatol. 2008; 158; 217-224.
11. Mackenzie KA, Wells JE, Lynn KL et al. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. Nephrol. Dial. Transplant. 2010; 25; 300-306.
12. O'Grady A, O'Kelly P, Murphy GM et al. COX-2 expression correlates with microvessel density in non-melanoma skin cancer from renal transplant recipients and immunocompetent individuals. Hum. Pathol. 2004; 35; 1549-1555.
13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100; 57-70.
14. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007; 26; 281-290.
15. Ratcliffe PJ. Understanding hypoxia signalling in cells - a new therapeutic opportunity? Clin. Med. 2006; 6; 573-578.
16. Hickey MM, Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr. Top. Dev. Biol. 2006; 76; 217-257.
17. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 1997; 94; 8104-8109.
18. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007; 26; 241-248.
19. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999; 59; 5830-5835.
20. Rezvani HR, Mazurier F, Cario-Andre M et al. Protective effects of catalase overexpression on UVB-induced apoptosis in normal human keratinocytes. J. Biol. Chem. 2006; 281; 17999-18007.
21. Wunderlich L, Paragh G, Wikonkal NM et al. UVB induces a biphasic response of HIF-1alpha in cultured human keratinocytes. Exp. Dermatol. 2008; 17; 335-342.
22. Eberhard A, Kahlert S, Goede V et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. [Erratum appears in Cancer. Res. 2000; 60; 3668.] Cancer Res. 2000; 60; 1388-1393.
23. Hillen F, van de Winkel A, Creytens D et al. Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. Melanoma Res. 2006; 16; 453-457.
24. Winter SC, Shah KA, Han C et al. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006; 107; 757-766.
25. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br. J. Cancer 1997; 76; 930-934.
26. Giatromanolaki A, Koukourakis MI, Pezzella F et al. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol. Oncol. 2008; 26; 219-224.
27. Giatromanolaki A, Koukourakis MI, Sivridis E et al. 'Invading edge versus inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J. Pathol. 2000; 192; 140-149.
28. Rosenberger C, Solovan C, Rosenberger AD et al. Upregulation of hypoxia-inducible factors in normal and psoriatic skin. J. Invest. Dermatol. 2007; 127; 2445-2452.
29. Kyzas PA, Stefanou D, Batistatou A et al. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2005; 131; 624-630.
30. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J. Clin. Invest. 2001; 107; 409-417.
31. Rasheed S, Harris AL, Tekkis PP et al. Assessment of microvessel density and carbonic anhydrase-9 (CA-9) expression in rectal cancer. Pathol. Res. Pract. 2009; 205; 1-9.
32. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J. Pathol. 1998; 184; 119-122.
33. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv. Oncol. 1996; 167-190.
34. Carrau R, Barnes E, Snyderman C et al. Tumor angiogenesis as a predictor of tumor aggressiveness and metastatic potential in squamous cell carcinoma of the head and neck. Invasion Metastasis 1995; 15; 197-202.
35. Rubin MA, Buyyounouski M, Bagiella E et al. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 1999; 53; 542-547.
36. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357; 539-545.
37. Rius J, Guma M, Schachtrup C et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008; 453; 807-811.
38. Lee S, Jilani SM, Nikolova GV et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 2005; 169; 681-691.
39. O'Grady A, Dunne C, O'Kelly P et al. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression. Histopathology 2007; 51; 793-804.
40. Kanitakis J, Euvrard S, Claudy A. Skin cancers in organ transplant recipients. J. Am. Acad. Dermatol. 2006; 54; 1115.
41. Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am. J. Transplant. 2008; 8; 2205-2211.
42. Muhleisen B, Petrov I, Gachter T et al. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate. Histopathology 2009; 55; 67-76.